Cresols
Medchemexpress LLC TL02-59 | 1315330-17-6 | 99.9% | 609.64 | 1 MG
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. It also inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. It is known to potently suppress acute myelogenous leukemia (AML) cell growth.
- Orally active, selective Src-family kinase Fgr inhibitor
- Inhibits Lyn and Hck
- Potently suppresses acute myelogenous leukemia (AML) cell growth
- Inhibits Fgr autophosphorylation in TF-1 cells
- Induces growth arrest in primary AML bone marrow samples
- Eliminates AML cells from the spleen and peripheral blood in a mouse model of AML
- Potential therapeutic agent for acute myelogenous leukemia (AML)
Medchemexpress LLC TL02-59 | 1315330-17-6 | 99.9% | 609.64 | 1 ML
TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. It inhibits Lyn and Hck, and potently suppresses acute myelogenous leukemia (AML) cell growth.
- Orally active and selective Src-family kinase Fgr inhibitor
- Inhibits Lyn and Hck
- Potently suppresses acute myelogenous leukemia (AML) cell growth
Medchemexpress LLC NY-ESO-1 (157-165) peptide | 202815-17-6 | 99.8% | 1094.35 | 5 MG
NY-ESO-1 (157-165) peptide is a peptide fragment derived from the NY-ESO-1 protein. It has the ability to activate the immune system. Specifically, in individuals who are positive for HLA-A2, it can be recognized by CD8+ T cells, thereby initiating an immune response. The NY-ESO-1 (157-165) peptide is expressed in various types of tumors, making it a potential target for tumor immunotherapy. It is considered a highly immunogenic epitope of NY-ESO-1 and can induce spontaneous or vaccine-induced T cell immune responses.
- Purity: 99.8%
- CAS number: 202815-17-6
- Molecular weight: 1094.35
- Formula: C49H79N11O13S2
- Appearance: Solid
- Color: White to off-white
- Sequence: Ser-Leu-Leu-Met-Trp-Ile-Thr-Gln-Cys
- Sequence shortening: SLLMWITQC
Medchemexpress LLC NY-ESO-1 (157-165) peptide | 202815-17-6 | 99.75% | 1094.35 | 10 MG
NY-ESO-1 (157-165) peptide is a peptide fragment derived from the NY-ESO-1 protein. It has the ability to activate the immune system, particularly in individuals who are HLA-A2 positive. This activation occurs as CD8+ T cells recognize the peptide, leading to an immune response. The NY-ESO-1 (157-165) peptide is present in various tumors, making it a potential target for tumor immunotherapy.
- Peptide fragment from NY-ESO-1 protein.
- Activates the immune system.
- Recognized by CD8+ T cells in HLA-A2 positive individuals.
- Triggers an immune response.
- Expressed in various tumors.
- Can be used as a target for tumor immunotherapy.
- Highly immunogenic epitope of NY-ESO-1.
- Can induce spontaneous or vaccine-induced T cell immune responses.